Standard cancer treatments may reduce mortality but not without significant adverse effects. They come at high cost to the patient and limit who can take them and for how long. While there is high unmet need for complementary oncologic and neurologic therapies, expanding research on the cancer-killing properties of many promising biopharmaceutical agents remains uncommercialized.

 

Pebble has innovated a platform of novel biopharmaceutical isolates to develop two-agent compounds that outperform standard of care in multiple expressions of ovarian, lung, colorectal, breast, prostate cancer, and leukemia.